Adopted the ICH Q10 pharmaceutical quality system
Ergopharm has aligned its site-wide quality system to the ICH Q10 Pharmaceutical Quality System framework, which reached Step 4 of the ICH process on 4 June 2008. The step formalises, across our manufacturing, laboratory and release functions, a single lifecycle-based model for maintaining product quality and driving continual improvement.
ICH Q10 describes a comprehensive model for a pharmaceutical quality system based on established quality-management concepts, and it complements the existing guidance on pharmaceutical development (ICH Q8) and quality risk management (ICH Q9). Rather than treating quality as a set of isolated GMP tasks, Q10 asks a manufacturer to manage quality across the whole product lifecycle, from development through routine commercial manufacture to product discontinuation. Ergopharm has adopted this framework as the organising structure for how its Advanced Research Centre in Vadodara operates day to day.
“A quality system is only as good as the management oversight behind it, and ICH Q10 gives that oversight a single, lifecycle-wide structure.”
The guideline is built around four elements, and Ergopharm has mapped each to a defined internal process. Process performance and product-quality monitoring is delivered through routine trending of in-process and finished-product results against agreed limits. Our corrective and preventive action (CAPA) system investigates deviations and out-of-specification results and confirms that fixes hold. Change management governs how modifications to methods, materials, equipment and processes are proposed, assessed for risk and approved before implementation. Management review provides the periodic senior-level oversight that confirms the system is functioning and directs resources to where trends indicate they are needed.
For our sterile injectable and oral-solid lines, this means the same lifecycle logic now connects development knowledge to routine production. Batch Manufacturing Records, Certificates of Analysis and the Product Quality Review are treated as connected sources of one quality signal rather than as separate paperwork exercises. Quality risk management under ICH Q9 sits underneath each element, so that monitoring, CAPA and change decisions are prioritised by their potential effect on the patient and on product quality.
Adoption is a matter of Ergopharm's own governance and does not represent any national marketing approval. It sets a common vocabulary and a common set of expectations for every function on site, and it establishes the management-review cadence through which senior staff hold the system to account. All performance figures referenced internally are illustrative and are used to drive improvement, not for external representation.
Key facts
- Instrument
- ICH Q10 Pharmaceutical Quality System
- Step 4 reached
- 4 June 2008
- Four elements
- Performance & quality monitoring, CAPA, change management, management review
- Complements
- ICH Q8 (development) and ICH Q9 (quality risk management)
This notice describes Ergopharm’s own packaging and processes and how they follow published standards; it does not assert a specific national marketing approval.